Feed TELIF
Summary
49 / 100 · Bulios Score
Valuation 65Growth -Profitability 20Quality 60Debt 52Stability 47
What speaks for it
- Out of every 100 CAD of revenue, 50 CAD is left as net profit.
- You pay 6.0 CAD for 1 CAD of yearly profit, little for its sector.
What to watch
- It reports a profit, yet spends more cash than it brings in.
- It passes only 2 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedP/E today 6.0
Biotechnology industry median
Today you pay 6.0 CAD for 1 CAD of yearly profit.
Valuation in detailIs it growing?
Revenue (CAD)
2022202320252026
Diluted EPS (CAD)
2022202320252026
There is not enough revenue history yet to say how fast it grows.
Growth in detailDoes it make money?
PoorlyWhere 100 CAD of revenue goes
- Cost of sales 63 CAD
- Sales and administration 150 CAD
- Taxes and other -164 CAD
- Net profit 50 CAD
Net profit, industry median (Biotechnology) -7.3 CAD
Out of every 100 CAD of revenue, 50 CAD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenCash and short-term investments $1.34M
Debt $2.72M
Free cash flow over 12 months -$6.31M
Over the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.